However, given the molecular properties of these drugs, basket trials that investigate efficacy of different PD-1 inhibitors across cancer patients independent of tumor site but dependent on their immunological status [16] or PD-1/PD-L1 expression levels may give us a more inclusive answer with regard to patient selection. This evidence concerns the gene CD274 and cancer.